問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Chang Gung Medical Foundation Chang Gung Memorial Hospital, Keelung

Link to Hospital

  • 1,089

    Total Beds

  • 275

    Total Doctors

  • shengyuan@cgmh.org.tw
  • Lin, Sheng-yuan
  • 02-24329292 #2082
  • 204Keelung CityAn LeNo. 222, Maijin Rd., Anle Dist., Keelung City 204015, Taiwan

Recruiting Trial

51Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

167Cases

2012-08-02 - 2013-06-25

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Terminated17Sites

2013-12-18 - 2015-10-31

Phase III

A Multicenter, Randomized, Double-blind Trial to Assess the Efficacy and Safety of ASC-01 in Patients with Major Depressive Disorder

  • Condition/Disease

    Major depressive disorder

  • Test Drug

    ASC-01

Participate Sites
12Sites

Terminated12Sites

藍先元
China Medical University Hospital

Division of Psychiatry

2013-08-01 - 2015-10-30

Phase III

A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naïve and Treatment-Experienced Korean and Taiwanese Subjects with Chronic Genotype 1 HCV Infection

  • Condition/Disease

    HCV Infection

  • Test Drug

    Sofosbuvir (SOF)/ledipasvir (LDV) fixed-dose combination (FDC) tablets

Participate Sites
13Sites

Terminated13Sites

2016-01-01 - 2017-04-25

Others

A 24-week Treatment, Randomised, Parallel-group, Double blinded, DoubleDummy, Multicenter Study to Assess the Efficacy and Safety of Aclidinium bromide/Formoterol fumarate compared with Individual Components and Placebo and Aclidinium bromide compared with Placebo when Administered to Patients with Stable Chronic Obstructive Pulmonary Disease

  • Condition/Disease

    Stable Chronic Obstructive Pulmonary Disease

  • Test Drug

    Aclidinium bromide/Formoterol fumarate

Participate Sites
8Sites

Recruiting1Sites

Terminated5Sites

Study ended1Sites

2016-11-01 - 2019-11-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting8Sites

2013-08-05 - 2015-11-30

Phase III

A Phase 3b, Multicenter, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Sofosbuvir plus Ribavirin in Treatment Naïve Subjects with Chronic Genotype 1, 2, 3 and 6 HCV Infection and in Treatment-Experienced Subjects with Chronic Genotype 2 HCV Infection

  • Condition/Disease

    HCV Infection

  • Test Drug

    Sofosbuvir

Participate Sites
13Sites

Terminated13Sites

2021-01-22 - 2023-03-23

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting2Sites

Recruiting8Sites

2014-11-03 - 2016-11-01

Phase II

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF AC 201 IN SUBJECTS WITH GOUT

  • Condition/Disease

    Osteoarthritis

  • Test Drug

    AC-201

Participate Sites
8Sites

Terminated7Sites

Study ended1Sites

黃春明
China Medical University Hospital

Division of Rheumatology

2006-07-20 - 2007-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2011-04-01 - 2019-03-19

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

1 12 13 14 15 16 17
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB